Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00218530 · ClinicalTrials.gov registry record · Phase 1
Effectiveness of Naltrexone and Lofexidine in Treating Detoxified Heroin Addicts - 1
A Phase 1 study, sponsored by National Institute on Drug Abuse (NIDA).
- Completed
- Registry status
- Phase 1
- Development phase
NCT00218530 is a Phase 1 study that has completed, run by National Institute on Drug Abuse (NIDA).
The verdict
NCT00218530, a Phase 1 study, has completed, sponsored by National Institute on Drug Abuse (NIDA).
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
Stress is one of the more common reasons cited by addicts for continual drug use and relapse. Treatment approaches that target both drug-induced and stress-induced relapse may prove to be more beneficial than targeting drug-induced relapse alone. Lofexidine is a drug that reduces the physical symptoms of opiate withdrawal and may prove to have stress-reducing capabilites in drug addicts. The purpose of this study is to determine the maximal safe dose of lofexidine tolerated in naltrexone-treated heroin addicts and to find an optimal lofexidine induction schedule.
Interventions
- DRUG Lofexidine
Trial Details
| Field | Value |
|---|---|
| Start Date | 2003-03 |
| Est. Completion | 2004-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00218530
The ClinicalTrials.gov registry entry for NCT00218530 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is National Institute on Drug Abuse (NIDA), which has 335 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lofexidine is the first listed.
NCT00218530 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00218530 about?
NCT00218530 is a clinical study titled "Effectiveness of Naltrexone and Lofexidine in Treating Detoxified Heroin Addicts - 1". Stress is one of the more common reasons cited by addicts for continual drug use and relapse. Treatment approaches that target both drug-induced and stress-induced relapse may prove to be more beneficial than targeting drug-induced relapse alone. Lofexidine is a drug that reduces the physical sympto...
What is the current status of trial NCT00218530?
This trial is currently completed. It is a Phase 1 study. The study started on 2003-03. Estimated completion is 2004-09.
What interventions are being tested in trial NCT00218530?
The interventions under investigation include: Lofexidine (DRUG).
Who is sponsoring clinical trial NCT00218530?
This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.